IP Verse

Anticancer Compositions - EP3226842

The patent EP3226842 was granted to Aragon Pharmaceuticals on Nov 25, 2020. The application was originally filed on Dec 3, 2015 under application number EP15817642A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3226842

ARAGON PHARMACEUTICALS
Application Number
EP15817642A
Filing Date
Dec 3, 2015
Status
Opposition Rejected
Mar 21, 2025
Grant Date
Nov 25, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TEVA PHARMACEUTICALSAug 25, 2021D YOUNGADMISSIBLE
ALFRED E TIEFENBACHERAug 24, 2021HAMM & WITTKOPPADMISSIBLE

Patent Citations (10) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2013184681
INTERNATIONAL-SEARCH-REPORTWO2013152342
INTERNATIONAL-SEARCH-REPORTWO2015023710
INTERNATIONAL-SEARCH-REPORTWO2015118015
OPPOSITIONUS2013345320
OPPOSITIONWO02080902
OPPOSITIONWO2013152342
OPPOSITIONWO2013184681
OPPOSITIONWO2014113260
OPPOSITIONWO2014167428

Non-Patent Literature (NPL) Citations (16) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- "assessment report EMA/646111/2011", European medicines agency, (20110623), XP055850254-
OPPOSITION- "CHMP Assessment Report For Intelence®", CHMP Assessment Report For Intelence®, (20080000), XP055850239-
OPPOSITION- "history of change for study : NCT02160756", clinicaltrials.gov, (20141113), XP055747378-
OPPOSITION- "History of Changes for Study: NCT02123758 A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer", Clinical Trials.gov, (20141202), XP055850235-
OPPOSITION- KUMAR P et al., "A Study on solubility enhancement methods for poorly water soluble drugs", American Journal of Pharmacological Sciences, (20130000), vol. 1, no. 4, pages 67 - 73, XP055850216-
OPPOSITION- Narkhede, Et Al, "Enhancement of solubility of Bicalutamide Drug using solid dispersion Technique", Pharma Science Monitor, (20121101), vol. 3, no. 4, pages 2739 - 2748, XP055864158-
OPPOSITION- R Kumari, Chandel P, Kapoor A, "Paramount Role of Solid Dispersion in Enhancement of Solubility", Indo Global Journal of Pharmaceutical Sciences, (20130101), vol. 3, no. 1, ISSN 22491023, pages 78 - 89, XP055215886-
OPPOSITION- Sancheti P P, Et Al, "Development and characterization of bicalutamide-poloxamer F68 solid dispersion systems", Pharmazie, (20080301), vol. 63, pages 571 - 575, XP055864155-
OPPOSITION- Srikanth M V, Et Al, "Studies on the Effect of Hydrophilic Carriers in the Dissolution Rate Enhancement of Poorly Soluble Drug, Bicalutamide", Research J. Pharm. And Tech., (20100101), vol. 3, no. 2, pages 592 - 595, XP055864176-
OPPOSITION- Sternberg Cora N, Et Al, "Progress in the Treatment of Advanced Prostate Cancer", American Society of Clinical Oncology Educational Book, (20140101), pages 117 - 131, XP055864149-
OPPOSITION- WEUTS et al., "Physicochemical Properties of the Amorphous Drug, Cast Films, and Spray Dried Powders to Predict Formulation Probability of Success for Solid Dispersions: Etravirine", J Pharm Sci Jan, (20110000), vol. 100, no. 1, pages 260 - 274, XP055850244-
OPPOSITION- HUANG Y et al., "Fundamental aspects of solid dispersion technology for poorly soluble drugs", Acta Pharmaceutica Sinica B, (20140000), vol. 4, no. 1, pages 18 - 25, XP055497465
OPPOSITION- VASCONCELOS et al., "Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs", Drug Discovery Today, (20071200), vol. 12, no. 23,24, pages 1068 - 1075, XP008162300
OPPOSITION- WILLIAMS et al., "Strategies to Address Low Drug Solubility in Discovery and Development", Pharmacol Rev, (20130100), vol. 65, pages 315 - 499, XP055157770
OPPOSITION- Sandrien Janssens et al, "review:physical chemistry of solid dispersions", Janssens Journal of Pharmacy and Pharmacology, (20090000), vol. 61, pages 1571 - 1586, XP055023760
OPPOSITION- Srinarong P et al, "Improved dissolution behavior of lipophilic drugs by solid dispersions:the production process as starting point for formulation considerations", Expert Opin., (20110000), vol. 8, no. 9, pages 1121 - 1140, XP055839893

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents